Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

This study has been terminated.
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Spanish Lung Cancer Group
ClinicalTrials.gov Identifier:
NCT00503971
First received: July 18, 2007
Last updated: October 19, 2012
Last verified: April 2008
  Purpose

This is an open label, non-randomized, sequential, phase I/II trial in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) with EGFR mutations after progression to Erlotinib. The study will have two parts. The first part (phase I) will be a dose finding (MTD) study to be implemented at three hospitals. The second part of the study (phase II) will asses the safety and efficacy of the combination. In this second part (phase II) patients will be treated with oral Erlotinib 150 mg P.O daily plus oral Vorinostat administered according to the results of the phase I. The study endpoints to be evaluated will include safety and response rate (RR) as primary endpoints and clinical benefit rate (CBR), time to progression, time to response, response duration and progression free survival as secondary endpoints. All the patients (phase I and II) will be treated until progression disease, unacceptable toxicity or withdrawal of the consent, and will be treated at the discretion of the principal investigator.


Condition Intervention Phase
Non-small Cell Lung Cancer
Drug: Vorinostat plus Erlotinib
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Sequential Phase I/II Trial of Oral Vorinostat in Combination With Erlotinib in Non-small-cell Lung Cancer Patients With Mutations at Epidermal Growth Factor Receptor With Disease Progression After Erlotinib Treatment

Resource links provided by NLM:


Further study details as provided by Spanish Lung Cancer Group:

Primary Outcome Measures:
  • MTD (Maximum Tolerated Dose)defined as the highest dose level at which < 2 out of 6 patients experienced a DLT. [ Time Frame: First cycle ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Efficacy: Objective response rate; Time to progression; Time to response Response duration;Progression free survival;Clinical Benefict Rate [ Time Frame: Along the study ] [ Designated as safety issue: No ]
  • Exploratory Endpoints: Molecular analysis (EGFR mutations; thioredoxin; Hsp70; methylation of 14-3-3 sigma and CHFR, EGFR mutation at serum (in blood samples from patients) [ Time Frame: baseline, after cycle 3 and at the end of treatment ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: December 2007
Study Completion Date: December 2011
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vorinostat plus erlotinib
Vorinostat plus erlotinib
Drug: Vorinostat plus Erlotinib

Phase I:

Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily

Phase II:

Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily

Other Name: Zolinza® and Tarceva®

Detailed Description:

SAMPLE:

Patients must have histologically-confirmed diagnosis of stage IIIB or IV NSCLC, with prior treatment with Erlotinib. In the phase I study the upper expected number of patients will be eighteen. In the phase II thirty two eligible patients will be included in the study. The enrollment period will be approximately 1.5 years. All patients will be treated with Erlotinib and Vorinostat regimen. Participating hospitals will be those of the Spanish Lung Cancer Group (SLCG).

For the phase I portion, there will be 3 sites: Dr. Noemi Reguart and Dr. Rafael Rosell, Institut Catala d'Oncologia, Hospital Germans Trias i Pujol, Badalona (Barcelona, Spain), Dr. Felip Cardenal, Institut Catalan d'Oncologia. Centre Sanitari i Universitari de Bellvitge (CSUB), Hospitalet de Llobregat (Barcelona, Spain) and Dr. Lola Isla, Hospital Clinico Lozano Blesa, (Zaragoza, Spain) For the phase II portion, 10 hospitals (adding 7 to the first 3) from the Spanish Lung Cancer Group (SLCG) will be involved. Hospitals will be included during phase I study.

OBJECTIVES AND HYPOTHESES Primary Phase I

(1) To determine the MTD of oral vorinostat in combination with erlotinib and to ensure that this treatment is sufficiently safe and tolerable to permit further study.

Phase II (1) To determine the percentage of patients free of progression at 12 weeks. Hypothesis: We considered that treatment was effective if we obtained a percentage of patients free of progression at 12 weeks higher than 60%.

Secondary

(1) To determine the CBR (clinical benefit rate), response rate, time to progression, time to response, response duration, and progression free survival in patients treated with vorinostat and erlotinib in combination.

Hypothesis: CBR should be of at least 25% and it will include stable disease for at least 3 months and objective RECIST response for at least 4 weeks.

Exploratory endpoints

Molecular analysis:

Main Objective: analysis of EGFR mutations (in exons 19, 20 and 21) in serum samples at baseline (before treatment), at three months of treatment and at the end of the treatment.

Secondary Objectives: retrospective analysis of molecular markers potentially related to drug sensitivity such as E-catherin protein expression, thioredoxin serum levels; Hsp70; methylation of 14-3-3r and CHFR.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed NSCLC
  2. Diagnosis of advanced stage IIIB with pleural effusion or IV NSCLC
  3. Previous disease progression after >= 3 months treatment with Erlotinib. Must tolerate erlotinib dose of 150 mg daily during the prior month.
  4. Have demonstrated mutations at epidermal growth factor receptor (EGFR) at Exon 19 or Exon 21 (Exon 19 mutations characterized by in-frame deletions (747-750), and Exon 21 mutations resulting in L858R substitutions).
  5. At least 18 years old.
  6. Measurable disease as defined by the presence of at least one lesion that can be accurately measured in at least one dimension using RECIST guidelines.
  7. At least 4 weeks from any prior major surgery or radiation therapy and have adequately recovered from the toxicities and/or complications
  8. ECOG performance status 0 to 2
  9. Adequate bone marrow function without the current use of colony stimulating factors.
  10. Adequate coagulation function.
  11. Adequate liver function
  12. Adequate renal function
  13. Non-sterilized premenopausal female, pregnancy test must be performed and patient must agree to use barrier methods of contraception. Male patients must agree to use an adequate method of contraception.
  14. Available for periodic blood sample analyses, study related assessments 15.Patient has the ability to understand and willingness to sign the informed consent form.

16.Patient is able to read, understand, and complete the study questionnaires.

Exclusion Criteria:

  1. Patient has been treated with any investigational agent for any indication within 4 weeks of study treatment.
  2. Patient previously treated with Vorinostat or any other HDAC inhibitor for any indication in the previous 30 days.
  3. Patient has history of hypersensitivity or intolerance to Erlotinib.
  4. Patient has an active infection or has received intravenous antibiotic, antiviral or antifungal medications with 2 weeks
  5. Patient with symptomatic central nervous system metastases with or without corticosteroids treatment.
  6. Inability to take and/or tolerate oral medications.
  7. Patient has known active hepatitis B or C infection,(HIV) HIV-related malignancy.
  8. Pregnant or breastfeeding.
  9. Patient with a history of gastrointestinal disease, surgery
  10. Patient with uncontrolled undercurrent illness or circumstances that could limit compliance with the study.
  11. History of malignancy except for inactive non-melanoma skin cancer and/or in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 5 years prior to study enrollment.
  12. Patient has had prescription or non-prescription drugs or other products known to influence CYP3A4 that cannot be discontinued prior to day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study medication.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00503971

Locations
Spain
Instituto Universitario Dexeus
Barcelona, Spain, 08028
Institut Catalá d'Oncologia, Centre Sanitari i Universitari de Bellvitge (CSUB)
Barcelona, Spain, 08907
Hospital Clinic
Barcelona, Spain, 08036
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain, 08025
Institut Catalá d'Oncología, Hospital Germans Trias i Pujol
Barcelona, Spain, 08916
Hospital La Paz
Madrid, Spain, 28046
Hospital Clínico Universitario de Valencia
Valencia, Spain, 46010
Hospital Clínico Lozano Blesa
Zaragoza, Spain, 50009
Sponsors and Collaborators
Spanish Lung Cancer Group
Merck Sharp & Dohme Corp.
Investigators
Principal Investigator: Teresa Moran, MD Medical Oncology Service. Institut Catala d'Oncologia- ICO. Hospital Germans Trias i Pujol. Badalona - Barcelona (Spain)
Study Chair: Dolores Isla, MD Medical Oncology Service. Hospital Clinico Lozano Blesa. Zaragoza. Spain
Study Chair: Felip Cardenal, MD Institut Catala d'Oncologia. Centre Sanitari i Universitari de Bellvitge (CSUB). Hospitalet de Llobregat (Barcelona). Spain
Study Chair: Bertomeu Massutti, MD Medical Oncology Service. General Hospital. Alicante. Spain
Study Chair: Rafael Rosell, MD Medical Oncology Service. Institut Catala d'Oncologia- ICO. Hospital Germans Trias i Pujol. Badalona - Barcelona (Spain)
Study Chair: Noemi Reguart, MD Medical Oncology Service. Hospital Clinic - Barcelona (Spain)
Principal Investigator: Amelia Insa, MD Medical Oncology Service. Hospital Clínico Universitario - Valencia (Spain)
Principal Investigator: Cinta Pallarés, MD Medical Oncology Service. Hospital de la Santa Creu i Sant Pau - Barcelona (Spain)
  More Information

No publications provided

Responsible Party: Spanish Lung Cancer Group
ClinicalTrials.gov Identifier: NCT00503971     History of Changes
Other Study ID Numbers: TARZO
Study First Received: July 18, 2007
Last Updated: October 19, 2012
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Spanish Lung Cancer Group:
Vorinostat
NSCLC
EGFR
Erlotinib

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Vorinostat
Erlotinib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors

ClinicalTrials.gov processed this record on August 19, 2014